Clinical trials: System Sclerosis
Multiple Sclerosis, Rehabilitation
Vigorous Cool Room Treadmill Training
People with multiple sclerosis (MS) are often offered walking aids and compensatory strategies rather than restorative rehabilitation.
- Conditions
- Multiple Sclerosis, Rehabilitation, Gait Disorders, Neurologic, Neuronal Plasticity
- Trial name
- NCT04066972
- Testing
- Body-weight supported treadmill training in a room cooled to 16°C
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Memorial University of Newfoundland
Amyotrophic Lateral Sclerosis
Intraspinal Transplantation of Autologous ADRC in ALS Patients
The goal of our nonrandomized, open label study is to investigate the safety and efficacy of autologous adipose derived mesenchymal regenerative cells (ADRC) transplantation into the individuals with diagnosed amyotrophic lateral…
- Trial name
- ADIPOSTEM (NCT03296501)
- Testing
- Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Mossakowski Medical Research Centre Polish Academy of Sciences
Relapsing-remitting Multiple Sclerosis
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
The purpose of this study is to compare the injection site reaction and injection site pain after subcutaneous administration of either Betaferon 250µg or Rebif 44µg using different autoinjectors.
- Trial name
- NCT00317941
- Testing
- Betaferon/Betaseron, Rebif
- Where
- 59 sites in France
- Volunteers
- 220 people
- Sponsor
- Bayer
Multiple Sclerosis
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
This is a Phase II/III, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of rituximab in adults with PPMS.
- Trial name
- OLYMPUS (NCT00087529)
- Testing
- rituximab
- Volunteers
- 439 people
- Sponsor
- Genentech, Inc.
Relapsing Multiple Sclerosis, Multiple Sclerosis
Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)
The main aim and overall objective of the study is to assess whether rituximab is non-inferior to cladribine for the treatment of relapsing MS.
- Trial name
- NOR-MS (NCT04121403)
- Testing
- Rituximab, Cladribine
- Where
- 11 sites in Norway
- Volunteers
- 267 people
- Sponsor
- Oslo University Hospital
Multiple Sclerosis, Healthy
COVID-19 Vaccine Response in Treated MS Patients
The primary goal of this study is to assess the impact of the two major disease modifying therapy (DMT) classes (B cell therapies and S1P modulators) on humoral and cell-mediated immunity to SARS- CoV-2 vaccination compared to…
- Trial name
- NCT05060354
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Severe Systemic Sclerosis
Phase I/II Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic Sclerosis
Systemic sclerosis (SSc) is a rare, severe and chronic systemic autoimmune disease (AD) characterized by vasculopathy, immune dysregulation and fibrosis leading to multi-organ dysfunction (primarily skin, lungs, heart…
- Trial name
- MSC-AT-SSc (NCT06722105)
- Testing
- 2 infusions of MSC, 1 infusion of MSC
- Volunteers
- 18 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis
Physical Activity Intervention for Individuals Newly Diagnosed With MS
The proposed study is a parallel-group randomized controlled trial (RCT) designed to establish the behavioral mechanism underlying a 16-week physical activity (PA) behavioral intervention through its effects on the…
- Trial name
- ActivNMS (NCT07731659)
- Testing
- COM-B-based Physical Activity Behavior Change Intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Illinois Chicago
Scleroderma, Diffuse
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis…
- Trial name
- NCT06655896
- Testing
- rapcabtagene autoleucel, rituximab
- Where
- 93 sites in United States, Argentina and 20 more
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients
Multiple sclerosis is the most common autoimmune disease of the central nervous system, most ranging in age from 40-20 years of age is associated with neurons inflammation and demyelination.
- Trial name
- NCT03150966
- Testing
- Nanocurcumin
- Where
- Iran
- Volunteers
- 41 people
- Sponsor
- Tabriz University of Medical Sciences
Multiple Sclerosis
Balance and Falls in Multiple Sclerosis
The study hypothesis is that for people with moderate to severe multiple sclerosis postural balance and walking improve and the risk of accidental falls are reduced after participating in a specific training intervention of 7…
- Trial name
- NCT02209467
- Testing
- Group balance training
- Where
- 7 sites in Sweden
- Volunteers
- 52 people
- Sponsor
- Örebro County Council
Multiple Sclerosis
Robot-assisted Gait Training in Patients With Multiple Sclerosis: Efficacy and Comparison With Traditional Methods
In Multiple Sclerosis (MS) gait disorders represent one of the most disabling aspect that strongly influence patient quality of life. The improvement of walking ability is a primary goal for rehabilitation treatment.
- Trial name
- NCT02291107
- Testing
- Lokomat (Hocoma, Zurich, Switzerland), Conventional Physiotherapy
- Where
- Italy
- Volunteers
- 17 people
- Sponsor
- Habilita, Ospedale di Sarnico
Scleroderma
Delving Into Participation Trends of Scleroderma Clinical Trials
Typically, specific demographic subsets tend to exhibit greater engagement in medical research. Nonetheless, there is insufficient research elucidating the trial characteristics influencing the participation of these particular…
- Trial name
- NCT06264492
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Multiple Sclerosis, Parkinson Disease
Intestinal Immunity in Neurologic Disease
The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases.
- Conditions
- Multiple Sclerosis, Parkinson Disease, REM Sleep Behavior Disorder
- Trial name
- NCT06329453
- Testing
- Colon Tissue Biopsy
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Yale University
Multiple Sclerosis, Relapsing-Remitting
A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
This was a retrospective non-interventional study (NIS) of adult (≥18 years) multiple sclerosis (MS) patients on ofatumumab therapy in the United Kingdom (UK) using secondary data.
- Trial name
- NCT06897657
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Resistance Training and Amino Pyridine in Multiple Sclerosis
Prolonged-release fampridine (SR-fampridine) can improving walking capacity in approximately 40% of MS patients suffering from this by overcoming partly or total conduction block due to demyelination.
- Trial name
- RETRAP (NCT02143167)
- Testing
- SR-fampridine
- Where
- 4 sites in Denmark
- Volunteers
- 40 people
- Sponsor
- University of Southern Denmark
Relapsing Remitting Multiple Sclerosis
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
To determine the efficacy and safety of an oral drug (BGC20-0134) in patients with relapsing remitting multiple sclerosis. Specifically, the cumulative number of new gadolinium enhancing lesions after 24 weeks of treatment with…
- Trial name
- NCT01037907
- Testing
- Pleneva TM BGC20-0134
- Where
- 35 sites in Belgium, France and 4 more
- Volunteers
- 173 people
- Sponsor
- Boston Scientific Corporation
Secondary Progressive Multiple Sclerosis
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with…
- Trial name
- NCT07299019
- Testing
- Orelabrutinib
- Where
- 69 sites in United States, Australia and 14 more
- Volunteers
- 990 people
- Sponsor
- Zenas BioPharma (USA), LLC
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis and the Effects of Ketogenic Diet Therapy
Multiple sclerosis (MS) is an inflammatory and immune-mediated neurological disease with multifactorial etiology. The specific etiopathogenetic mechanisms of MS are still unknown but it is clear that it results from a combination…
- Trial name
- NCT06715436
- Testing
- Mediterranean Diet, Ketogenic Diet, Control group
- Where
- Italy
- Volunteers
- 111 people
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
Chronic Pancreatitis, Inflammatory Bowel Diseases
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect…
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- GREAT1 (NCT04306939)
- Testing
- venipuncture, Questionnaires, Additional Sample Collections
- Where
- United States
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.